Article

Brian LaMoreaux, MD: Practicing Rheumatology During and After COVID-19

Medical director of Horizon Therapeutics discusses changes in rheumatology practices as a result of the ongoing pandemic.

While it is safe to say the role of telemedicine will never be the same in the wake of the coronavirus disease 2019 (COVID-19) outbreak, not every specialist has been able to take their practices completely virtual.

Many of these specialists are rheumatologists—who, due to the nature of the diseases they treat, cannot always effectively assess their patients through telemedicine as they could with a traditional in-person visit.

“When these things first start, its really tough to have an idea of how widespread it’s going to become, how much it is going to impact our daily lives,” said Brian Lamoreaux, MD, a medical director with Horizon Therapeutics in a recent interview with HCPLive®. “I think it’s safe to say we have that answer now.”

With rheumatic conditions requiring such an intimate relationship with patients, the challenges faced by rheumatologists during the ongoing outbreak have been unique. Couple this with a surge in hydroxychloroquine prescriptions, which is a staple in the treatment of patients with lupus, and rheumatologists have been confronted with a myriad of obstacles to overcome in recent months.

To learn more about the unique challenges facing rheumatologists during this difficult time, HCPLive invited LaMoreaux to take part in an HCPLive House Call. In addition to his role with Horizon Therapeutics, LaMoreaux also lends his time and expertise at a clinic in Chicago.

The following segment from the aforementioned HCPLive House Call examines the adoption of telemedicine in rheumatology and the long-term impact of COVID-19 on the field.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.